PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Virology (IVM), Centre for Molecular Biology of Inflammation, University of Muenster, Von-Esmarch-Straße 56, 48149, Münster, North Rhine-Westphalia, Germany.\', \'Translational Pediatrics, Department of Pediatrics, University Hospital Wuerzburg, 97080, Würzburg, Bavaria, Germany.\', \'Center for Infection Research, University Wuerzburg, 97080, Würzburg, Bavaria, Germany.\', \'Cluster of Excellence RESIST (EXC 2155, Hannover Medical School, 30625, Hannover, Lower Saxony, Germany.\', \'Research Group Regulatory Mechanisms of Inflammation, Institute of Medical Biochemistry, Centre for Molecular Biology of Inflammation, University of Muenster, 48149, Münster, North Rhine-Westphalia, Germany.\', \'CiM-IMPRS Graduate School, University of Muenster, 48149, Münster, North Rhine-Westphalia, Germany.\', \'Atriva Therapeutics GmbH, 72072, Tübingen, Baden-Württemberg, Germany.\', \'Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University, 72074, Tübingen, Baden-Württemberg, Germany.\', \'Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany.\', \'Faculty of Biology and Psychology, University Goettingen, 37077, Göttingen, Lower Saxony, Germany.\', \'Interdisciplinary Center of Clinical Research (IZKF), Medical Faculty, University of Muenster, 48149, Münster, North Rhine-Westphalia, Germany.\', \'Institute of Virology (IVM), Centre for Molecular Biology of Inflammation, University of Muenster, Von-Esmarch-Straße 56, 48149, Münster, North Rhine-Westphalia, Germany. ludwigs@uni-muenster.de.\', \'Interdisciplinary Center of Clinical Research (IZKF), Medical Faculty, University of Muenster, 48149, Münster, North Rhine-Westphalia, Germany. ludwigs@uni-muenster.de.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s00018-021-04085-1
?:doi
?:hasPublicationType
?:journal
  • Cellular and molecular life sciences : CMLS
is ?:pmid of
?:pmid
?:pmid
  • 35013790
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all